Drug updated on 4/16/2024
| Dosage Form | Tablet (oral; linagliptin/ metformin; 2.5 mg /500 mg, 2.5 mg/850 mg, 2.5 mg/1000 mg) |
| Drug Class | Dipeptidyl peptidase-4 inhibitors and biguanides |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Summary
- Linagliptin and metformin hydrochloride (Jentadueto) is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. It has shown superior efficacy compared to linagliptin alone, particularly in patients exhibiting marked hyperglycemia.
- A study evaluated Jentadueto's effectiveness and safety against linagliptin monotherapy for treating newly diagnosed type 2 diabetes mellitus.
- In terms of effectiveness, the combination therapy resulted in a more pronounced reduction in HbA1c levels than those receiving linagliptin alone over a period of 24 weeks. This finding suggests that Jentadueto is more effective across diverse patient subgroups irrespective of their baseline HbA1c, age, body mass index (BMI), renal function, or racial backgrounds.
- Regarding safety considerations, adverse events were reported slightly higher among patients on combination therapy at 8.8% versus those on linagliptin monotherapy at 5.7%. However, no severe hypoglycemia incidents were reported, indicating both treatment modalities have relatively safe profiles.
- Subgroup analysis revealed that individuals with significant hyperglycemia benefited consistently from the combination therapy regardless of different demographics and clinical characteristics, making it a viable initial treatment option for this population subset.
- Despite being based on one study only, which necessitates further research for corroborating these findings, current data positions Jentadueto as potentially beneficial first-line treatment strategy due to its superior efficacy coupled with the absence of severe hypoglycemic episodes when compared to other therapeutic agents within this category.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Jentadueto (linagliptin and metformin hydrochloride) Prescribing Information. | 2023 | Boehringer Ingelheim Pharmaceuticals, Inc. Ridgefield, CT |
Randomized Controlled Trials
| Document Title | Sex Distribution | Year | Source |
|---|---|---|---|
| Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia. | 316Subjects F: 54% M: 46% | 2016 | Postgraduate Medicine |
Document Title
Sex Distribution:
F:54%
M:46%
316Subjects
Year:
2016
Source:Postgraduate Medicine
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan—2022 update. | 2022 | AACE Endocrine Practice |
| Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update. | 2020 | Canadian Journal of Diabetes |